Vericel (NASDAQ:VCEL – Get Free Report) and C4 Therapeutics (NASDAQ:CCCC – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Valuation & Earnings
This table compares Vericel and C4 Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vericel | $276.26 million | 8.50 | $16.52 million | $0.42 | 109.52 |
| C4 Therapeutics | $35.95 million | 11.00 | -$104.99 million | ($1.19) | -3.00 |
Risk & Volatility
Vericel has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500.
Profitability
This table compares Vericel and C4 Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vericel | 7.35% | 6.41% | 4.61% |
| C4 Therapeutics | -297.76% | -50.68% | -33.22% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Vericel and C4 Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vericel | 1 | 2 | 4 | 0 | 2.43 |
| C4 Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Vericel presently has a consensus target price of $55.50, indicating a potential upside of 20.65%. C4 Therapeutics has a consensus target price of $7.75, indicating a potential upside of 116.78%. Given C4 Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than Vericel.
Insider & Institutional Ownership
78.8% of C4 Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Vericel beats C4 Therapeutics on 8 of the 14 factors compared between the two stocks.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
About C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
